Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 8 Sept 2026Clinical review pending
Saved on this device
!
Cancer may present through biliary sepsis
Gallbladder carcinoma can obstruct or invade the hilum and present with cholangitis, empyema, perforation or liver abscess rather than an orderly cancer-clinic presentation.
Action: Resuscitate sepsis, obtain cultures and cross-sectional imaging, begin an appropriate biliary antimicrobial regimen, and coordinate drainage or surgery with acute and HPB specialists while preserving a route to later staging.
Synopsis
Recognise suspected and incidental gallbladder carcinoma, preserve pathological and operative information, stage before definitive treatment, and identify who needs specialist completion surgery or oncological care.
Most gallbladder cancers are adenocarcinomas and may be discovered incidentally after cholecystectomy or during imaging for pain, weight loss or jaundice.
Risk rises with chronic gallbladder inflammation, especially long-standing stones; porcelain gallbladder, large polyps and congenital biliary abnormalities alter concern but do not replace tissue diagnosis.
Obtain staging-quality contrast CT of chest, abdomen and pelvis; MRI can clarify liver, hilar and bile-duct involvement when CT anatomy is incomplete.
Key red flags
A gallbladder mass, asymmetric wall thickening, invasion of adjacent liver or unexplained hilar obstruction requires specialist cancer review rather than routine cholecystectomy.
Jaundice in gallbladder cancer often indicates advanced local or nodal disease and requires careful vascular and segmental biliary mapping.
An unexpected cancer on a cholecystectomy specimen must trigger complete pathology review and staging before assuming that the original operation was definitive.
Infected complication
Fever, rigors, hypotension or a tender obstructed gallbladder demands acute source-control assessment alongside the malignancy pathway.
Investigation priorities
01
Specialist pathology reviewFirst step
Confirm histological type, depth, margins and adverse features after incidental discovery.
Management branches
Incidental T1aConfirm whether cholecystectomy was complete
Histology shows adenocarcinoma confined to lamina propria with clear cystic-duct and liver-bed margins.
Request specialist pathology confirmation of T1a depth and verify an intact specimen and clear margins.
Review staging imaging and operative documentation for unexpected disease, perforation or dissemination.
Key medicines
Adjuvant capecitabine after resected biliary tract cancer: specialist BILCAP-derived scheduleFor specialist guideline-supported off-label adjuvant biliary use after recovery from resection, the BILCAP-derived schedule is capecitabine 1,250 mg/m² orally twice daily on days 1–14 of each 21-day cycle for eight cycles, approximately six months. Take morning and evening doses within 30 minutes after food; swallow tablets whole with water, without crushing or cutting. Oncology calculates and rounds the body-surface-area dose to available strengths and applies toxicity holds/reductions.Test DPD before treatment: complete deficiency is contraindicated and partial deficiency needs a reduced specialist starting strategy. Exclude severe hepatic impairment, severe cytopenias, previous severe unexpected fluoropyrimidine reactions and product hypersensitivity. Do not start if neutrophils are below 1.5 × 10⁹/L or platelets below 100 × 10⁹/L; interrupt if on-treatment counts fall below 1.0 or 75 × 10⁹/L respectively. At Cockcroft–Gault CrCl 30–50 mL/min reduce the 1,250 mg/m² starting dose to 75%; below 30 do not start, and discontinue if it falls below 30 during treatment. Allow at least four weeks after stopping brivudine before capecitabine. Monitor INR/PT closely with warfarin and adjust anticoagulation; avoid allopurinol and monitor phenytoin concentrations/toxicity. Pregnancy is contraindicated; effective contraception continues for six months after the last dose for women and three months for men with partners of reproductive potential. Stop breastfeeding during treatment and for two weeks afterwards. Check FBC, renal/hepatic function and toxicity before each cycle. Stop and contact oncology for diarrhoea, stomatitis, fever, chest pain, dehydration or painful hand-foot reaction.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.